Shorter course antibiotic therapy (SCAT): Principles, current data, and caveats

Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures

Volumn , Issue , 2007, Pages 337-370

  Craven, Donald E ^a,b   McQuillen, Daniel P ^a,b   Ooi, Winnie W ^a,b   Jacoby, George A ^a,c   Rael, Efren L ^a   Craven, Kathleen Steger ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Consultant in Infectious Diseases and Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855313499     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (123)

1. Naylor CD, Guyatt GH. Users’ guides to the medical literature. X. How to use an article reporting variations in the outcomes of health services. The evidence-based medicine working group. J Am Med Assoc 1996; 275:554-8.
2. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27:520-32.
3. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925-32.
4. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
5. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10:S122-9.
6. David DR. In: Cohen JP, ed. Short-course antibiotic therapy. 2nd ed. New York: Mosby, 2004:1765-89.
7. Cohn DL. Treatment of latent tuberculosis infection. Semin Respir Infect 2003; 18:249
8. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32:623-32.
9. Guillemot D, Carbon C, Balkau B. Low dosage and long treatment duration of betalactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. J Am Med Assoc 1998; 279: 365-70.
10. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163:972-8.
11. Maki D, Schuna A. A study of antimicrobial misuse in a university hospital. Am J Med Sci 1987; 275:271-82.
12. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36:1433-7.
13. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5:1033-48.
14. Duncan RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol 1997; 18:260-6.
15. Duncan RA. Antimicrobial Stewardship. In: Lautenbach EWK, ed. Practical Handbook for Hospital Epidmiologists. 2nd ed. Thorofare, New Jersey: Slack Inc., 2004:199-209.
16. Burke JP. Antibiotic resistance-squeezing the balloon? J Am Med Assoc 1998; 280:1270-1.
17. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22:872-8.
18. MacGowan AP. Role of pharmacokinetics and pharmacodynamics: does the dose matter? Clin Infect Dis 2001; 33(Suppl. 3):S238-9.
19. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-92.
20. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380-91.
21. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100-7.
22. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050-8.
23. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160:1399-408.
24. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
25. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005; 40:1748-55.
26. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Infectious Diseases Society of America. Clin Infect Dis 1997; 25:574-83.
27. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 1997; 16:680-95.
28. Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003; 63:2169-84.
29. Wannamaker LW, Rammelkamp CH Jr, Denny FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med 1951; 10:673-95.
30. Wannamaker LW, Denny FW, Perry WD, et al. The effect of penicillin prophylaxis on streptococcal disease rates and the carrier state. N Engl J Med. 1953; 249:1-7.
31. Schwartz RH, Wientzen RL Jr, Pedreira F, Feroli EJ, Mella GW, Guandolo VL. Penicillin V for group A streptococcal pharyngotonsillitis. A randomized trial of seven vs ten days’ therapy. J Am Med Assoc 1981; 246:1790-5.
32. Gerber MA, Randolph MF, Chanatry J, Wright LL, De MK, Kaplan EL. Five vs. ten days of penicillin V therapy for streptococcal pharyngitis. Am J Dis Child 1987; 141:224-7.
33. Pichichero ME. Short course antibiotic therapy for respiratory infections: a review of the evidence. Pediatr Infect Dis J 2000; 19:929-37.
34. Adam D, Scholz H, Helmerking M. Short-course antibiotic treatment of 4782 cultureproven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. J Infect Dis 2000; 182:509-16.
35. McCarty JM. Clarithromycin in the management of community-acquired pneumonia. Clin Ther 2000; 22:281-94.
36. Williams JW Jr, Holleman DR Jr, Samsa GP, Simel DL. Randomized controlled trial of 3 vs. 10 s of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. J Am Med Assoc 1995; 273:1015-21.
37. Casiano RR. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991; 91:27S-30S.
38. Khong TK. Shortened therapies in acute sinusitis. Hosp Pract 1996; 31:11-3.
39. David DJ, Cooter RD. Craniofacial infection in 10 years of transcranial surgery. Plast Reconstr Surg 1987; 80:213-25.
40. Murphy TF, Kirkham C, Sethi S, Lesse AJ. Expression of a peroxiredoxin-glutaredoxin by Haemophilus influenzae in biofilms and during human respiratory tract infection. FEMS Immunol Med Microbiol 2005; 44:81-9.
41. Wilson R. Bacteria and airway inflammation in chronic obstructive pulmonary disease: more evidence. Am J Respir Crit Care Med 2005; 172:147-8.
42. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J Am Med Assoc 1995; 273:957-60.
43. Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in Chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172:195-9.
44. Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997; 9:141-6.
45. Lode H, Schaberg T. Azithromycin in lower respiratory tract infections. Scand J Infect Dis Suppl 1992; 83:26-33.
46. Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J Antimicrob Chemother. 1996; 37 (Suppl. C):93-101.
47. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003; 37:1405-33.
48. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27-S72.
49. Mandell LA, File TM, Jr. Short-course treatment of community-acquired pneumonia. Clin Infect Dis. 2003; 37:761-63.
50. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004; 20:555-63.
51. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 regimens of telithromycin once daily compared with a 10 regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54:515-23.
52. File TM Jr, Mandell LA, Leach T, Dostov K, Georgiev O. 5-day, short-course gemifloxacin Tehrapy to treat community-acquired pneumonia. Interscience Congress of Antimicrobial Therapy & Chemotherapy, New Orleans, LA. 9-22-2005. Ref Type: Abstract
53. O’Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:828-33.
54. Drehobl MA. Use of a large, extended release 2 g dose of aziathromycin for treatment of community-acquired pneumonia. 44th Interscience Congress of Antimicrobial Agents and Chemotherapy (L660). 9-20-2004. Ref Type: Abstract.
55. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-82.
56. Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004; 26:48-62.
57. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
58. Dennesen PJ, Van DV, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-5.
59. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early predictor of outcome. Crit Care Med 2003; 31(3):676-82.
60. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-9.
61. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11.
62. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. J Am Med Assoc 2003; 290:2588-98.
63. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396-402.
64. Duflo F, Debon R, Goudable J, Chassard D, Allaouchiche B. Alveolar and serum oxidative stress in ventilator-associated pneumonia. Br J Anaesth 2002; 89:231-6.
65. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171:48-53.
66. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29:745-58.
67. Gupta MN, Sturrock RD, Field M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology (Oxford). 2001; 40:24-30.
68. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillinclavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. J Am Med Assoc 2005; 293:949-55.
69. Naber KG. Treatment options for acute uncomplicated cystitis in adults. J Antimicrob Chemother 2000; 46(Suppl. A):23-7.
70. Lutters M, Vogt N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev 2002; CD001535.
71. Vogel T, Verreault R, Gourdeau M, Morin M, Grenier-Gosselin L, Rochette L. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004; 170:469-73.
72. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med 2002; 113 (Suppl. 1)A:80S-4S.
73. Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003; 17:303-2.
74. Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 2002; 113(Suppl. 1)A:67S-79S.
75. Dow G, Rao P, Harding G, et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis 2004; 39:658-64.
76. Kahan NR, Chinitz DP, Kahan E. Physician adherence to recommendations for duration of empiric antibiotic treatment for uncomplicated urinary tract infection in women: a national drug utilization analysis. Pharmacoepidemiol Drug Saf 2004; 13:239-42.
77. Wigton RS, Longenecker JC, Bryan TJ, Parenti C, Flach SD, Tape TG. Variation by specialty in the treatment of urinary tract infection in women. J Gen Intern Med 1999; 14:491-4.
78. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:2330-8.
79. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-80.
80. Malfertheiner P, Megraud F, O’Morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9:1-2.
81. Buckley MJ, Xia HX, Hyde DM, Keane CT, O’Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42:2111-5.
82. Wong WM, Gu Q, Wang WH, et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin Infect Dis 2003; 37:882-9.
83. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161:1217-20.
84. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136:13-24.
85. Calvet X, Ducons J, Guardiola J, et al. One-week triple versus quadruple therapy for Helicobacter pylori infection - a randomized trial. Aliment Pharmacol Ther 2002; 16:1261-7.
86. Prazeres MP, De Magalhaes Queiroz DM, Campos Barbosa DV, et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 2002; 46:2021-3.
87. Xia HX, Fan XG, Talley NJ. Clarithromycin resistance in Helicobacter pylori and its clinical relevance. World J Gastroenterol 1999; 5:263-6.
88. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463-9.
89. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10:1029-33.
90. de Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345(8953):817-20.
91. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20:99-107.
92. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2003; CD003840.
93. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002; 162:153-60.
94. de Boer WA, Driessen WM, Tytgat GN. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9:633-38.
95. de Boer WA. How to achieve a near 100% cure rate for Helicobacter pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996; 22:313-6.
96. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3:54-8.
97. Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158:633-8.
98. Kubota K, Barrett TJ, Ackers ML, Brachman PS, Mintz ED. Analysis of Salmonella enterica serotype Typhi pulsed-field gel electrophoresis patterns associated with international travel. J Clin Microbiol 2005; 43:1205-9.
99. Nguyen TC, Solomon T, Mai XT, et al. Short courses of ofloxacin for the treatment of enteric fever. Trans R Soc Trop Med Hyg 1997; 91:347-9.
100. Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404-10.
101. Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 2000; 44:1855-9.
102. Islam A, Butler T, Kabir I, Alam NH. Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. Antimicrob Agents Chemother 1993; 37:1572-5.
103. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(Suppl. 1):S47-65.
104. Fenton KA, Ison C, Johnson AP, et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 2003; 361:1867-9.
105. Sexually transmitted disease treatment guidelines, 2006. Centers for Disease Control and Prevention. MMWR Recomm Rep 2006; 55:1-94.
106. Updates to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. Centers for Disease Control and Prevention. MMWR 2007; 56:332-6.
107. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. J Am Med Assoc 1995; 274:545-9.
108. Wilson WR. Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis. J Am Med Assoc 1992; 267:279-80.
109. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406-10.
110. Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998; 27:1470-4.
111. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-434.
112. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109:619-24.
113. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med 1994; 121:873-6.
114. Fortun J, Navas E, Martinez-Beltran J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33:120-5.
115. Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125:969-74.
116. Torres-Tortosa M, de CM, Vergara A, Sanchez-Porto A, et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cadiz. Eur J Clin Microbiol Infect Dis 1994; 13:559-64.
117. Miro JM, del RA, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003; 21:167-vi.
118. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002; 30:476-89.
119. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002; 23:759-69.
120. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249-72.
121. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066-72.
122. Li JZ, Winston LG, Moore DH, Bent J. Efficacy of short-course antibiotic therapy regimens for community acquired pnuemonia: a meta-analysis. Am J Med 2007; 120(9):783-90.
123. File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-aquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60(1): 112-20.